Skip to main content
padlock icon - secure page this page is secure

Chemotherapy with si-RNA and Anti-Cancer Drugs

Buy Article:

$68.00 + tax (Refund Policy)

Background: To treat cancer, chemotherapy is a key therapeutic approach which is associated with several limitations. This chemotherapeutical agent exhibits multi drug resistance coupled with undesirable side effects. This multidrug resistance is exhibited by tumor cell due to actuation of drug out flow mechanism, programmed cell death and protection mechanisms etc. One of the therapeutic approaches to cure cancer is RNA interference (RNAi). Small interfering RNA (si-RNA) is considered as a major therapeutic tool used to control expression of a particular gene. It is a well known fact that intake of more drugs can lead to cancer chemo resistance, thus siRNA based therapeutic approach is under scrutiny to cure cancer.

Methods: This review article gives an overview of various combination approaches for si-RNA with chemotherapeutics. Further, article highlights the potential of nanotechnology to improve bioavailability of drug and bio-therapeutics at the site of action.

Results: Combination chemotherapy is employed in clinics as a main cancer treatment tool to suppress multidrug resistance in cancer. On the other hand, suitable protective carrier is needed due to the stability issues and small size of si-RNA. To overcome these drawbacks associated with siRNA currently, nanotechnology based approaches have been widely used.

Conclusion: Delivery of anti-cancer drugs with si-RNA will be one of important intermingled approach to reduce duration of chemotherapy and improve therapeutic outcomes in cancer patient.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Nanotechnology; RNAi; cancer; clinical trial; combination therapy; si-RNA

Document Type: Review Article

Publication date: March 1, 2018

This article was made available online on September 5, 2017 as a Fast Track article with title: "Chemotherapy with si-RNA and Anti-Cancer Drugs".

More about this publication?
  • The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.

    The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.

    The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more